The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Expected Market Size Of The Oral Biologics & Biosimilar Drugs Market In 2026 And How Much Will It Reach By 2030?
The oral biologics & biosimilar drugs market size has experienced substantial expansion in recent years. This market is expected to increase from $8.6 billion in 2025 to $10.41 billion in 2026, achieving a compound annual growth rate (CAGR) of 21.0%. Contributing factors to its historical growth include the limited availability of oral biologics, a dependency on injectable biologics, the escalating prevalence of autoimmune and inflammatory diseases, a rising patient preference for cost-effective therapies, and the early approvals of monoclonal antibody drugs.
The oral biologics & biosimilar drugs market size is projected to undergo significant expansion in the upcoming years. It will grow to $17.17 billion in 2030 at a compound annual growth rate (CAGR) of 13.3%. This anticipated growth during the forecast period can be attributed to several factors, including the development of advanced oral biologics, the expanding pipeline of biosimilar drugs, increasing adoption rates of combination therapies, the rise of digital health platforms for monitoring patients, and growing regulatory support for biosimilar approvals. Noteworthy trends over the forecast horizon involve the increasing acceptance of oral biologics and biosimilar drugs, a heightened focus on managing chronic diseases using biologics, the expansion of distribution channels through hospitals and retail pharmacies, an increase in patient awareness and receptiveness to biosimilars, and the ongoing development of targeted therapies for autoimmune and inflammatory conditions.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3792&type=smp
Which Drivers Are Advancing The Oral Biologics & Biosimilar Drugs Market Growth?
The increasing incidence of chronic illnesses such as arthritis, asthma, and cancer is projected to be a primary catalyst for the oral biologics and biosimilar market. Factors like prolonged working hours, insufficient physical activity, and unhealthy eating and drinking habits contribute to the widespread nature of chronic diseases, for which biologics are increasingly employed as a treatment. Biologics work by activating the immune system’s response against cancer cells, thereby assisting the body in eliminating them. For instance, according to a United Nations article published in May 2023, the proportion of global deaths attributed to chronic diseases is expected to rise to 70% of total deaths by 2030, with the global burden of chronic disease anticipated to reach about 60%. Thus, the growing prevalence of chronic diseases is forecast to significantly increase the demand for biologics and biosimilars, consequently propelling the growth of the oral biologics & biosimilar drugs market.
What Segment Types Are Included In The Oral Biologics & Biosimilar Drugs Market Analysis?
The oral biologics & biosimilar drugs market covered in this report is segmented –
1) By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors
2) By Disease: Asthma, Crohn’s Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis and Others
3) By Molecule Type: Proteins & Peptides, Monoclonal Antibodies, Other Molecule Types
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Lymphocyte Modulators: Fingolimod, Ocrelizumab, Natalizumab
2) By Interleukin Inhibitors: Ustekinumab, Secukinumab, Guselkumab
3) By Tumor Necrosis Factor-Alpha Inhibitors: Adalimumab, Certolizumab Pegol, Golimumab
Which Trends Are Influencing The Direction Of The Oral Biologics & Biosimilar Drugs Market?
Leading companies within the oral biologics and biosimilar markets are directing their efforts toward novel products, such as incretin triagonists, with the aim of improving patient well-being, enhancing medication effectiveness, and offering alternatives to therapies traditionally delivered by injection. Incretin triagonists represent a class of drugs that activate GLP-1, GIP, and glucagon, three hormone receptors simultaneously, which play a role in regulating blood sugar, appetite, and metabolism. For instance, in October 2024, Rani Therapeutics Holdings Inc., a biotechnology company based in the US, released updated preclinical pharmacokinetic data validating the transenteric delivery of a GLP-1 incretin triagonist. Their RaniPill, an oral capsule specifically designed for administering biologics that usually require injections, successfully delivered an incretin triagonist that targets GLP-1, GIP, and glucagon receptors, which are essential in the treatment of obesity. The RaniPill demonstrated effectiveness on par with subcutaneous injections, providing a needle-free method with significant bioavailability and adaptable dosing, thus establishing its potential as a promising treatment for obesity drug candidates.
Which Key Players Are Active In The Oral Biologics & Biosimilar Drugs Market?
Major companies operating in the oral biologics & biosimilar drugs market are Novartis International AG, Rani Therapeutics Holdings Inc., Eli Lilly and Company, AstraZeneca plc, Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals Inc., BiosanaPharma, Entera Bio Ltd., Allergan plc, Emisphere Technologies Inc., Enteris BioPharma Inc., Chiasma Inc., Allena Pharmaceuticals Inc., Gelgen Corporation, 3SBio Inc., Innovent Biologics Inc., GlaxoSmithKline PLC, Concord Biotech Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., Allergan Pharmaceuticals International Limited, Mylan N.V., Pfizer Inc., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd.
Access The Complete Oral Biologics & Biosimilar Drugs Market Report:
Which Region Holds The Largest Share In The Oral Biologics & Biosimilar Drugs Market?
North America was the largest region in the oral biologics and biosimilar drugs market in 2025. The Middle East is expected to be the fastest growing region in the oral biologics & biosimilar drugs market report during the forecast period. The regions covered in the oral biologics & biosimilar drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Oral Biologics & Biosimilar Drugs Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=3792&type=smp
Browse Through More Reports Similar to the Global Oral Biologics & Biosimilar Drugs Market 2026, By The Business Research Company
Dental Services Market Report 2026
https://www.thebusinessresearchcompany.com/report/dental-services-global-market-report
Dental Practice Management Market Report 2026
https://www.thebusinessresearchcompany.com/report/dental-practice-management-global-market-report
Dental X Ray Equipment Market Report 2026
https://www.thebusinessresearchcompany.com/report/dental-x-ray-equipment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model